Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal C conjugate vaccine

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  de Voer, Richarda M ^a,b   Mollema, Liesbeth ^a   Schepp, Rutger M ^a   de Greeff, Sabine C ^a   van Gageldonk, Pieter G M ^a   de Melker, Hester E ^a   Sanders, Elisabeth A M ^b   Berbers, Guy A M ^a   van der Klis, Fiona R M ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; POLYSACCHARIDE; SEROGROUP C MENINGOCOCCAL CONJUGATE VACCINE; TETANUS TOXOID;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; BACTERIAL IMMUNITY; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; IMMUNIZATION; INFANT; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NETHERLANDS; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEROPREVALENCE; ANTIBODY SPECIFICITY; EPIDEMIOLOGY; IMMUNITY; IMMUNOLOGY; MIDDLE AGED; NEWBORN; PREVENTIVE HEALTH SERVICE;

NEISSERIA MENINGITIDIS SEROGROUP C;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODY SPECIFICITY; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; IMMUNITY; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; MALE; MENINGOCOCCAL VACCINES; MIDDLE AGED; NEISSERIA MENINGITIDIS, SEROGROUP C; NETHERLANDS; POLYSACCHARIDES; SEROEPIDEMIOLOGIC STUDIES; TETANUS TOXOID; YOUNG ADULT;

EID: 77957923744     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012144     Document Type: Article

References (42)

1. de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Derende A (2006) Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 25: 79-80.
2. Gezondheidsraad/Health Council of the Netherlands. (2002) Universal vaccination against meningococcal serogroup C and pneumococcal disease. No. 2001/27E, The Hague.
3. Neppelenbroek SE, de Vries M, de Greeff SC, Timen A (2002) 'da's goed gedaan? Woordverslag van de landelijke vaccinatiecampagne meningokokken C. ISBN 90-72779-38-X. 2003. GGD Nederland.
4. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364: 365-367.
5. Larrauri A, Cano R, Garcia M, Mateo S (2005) Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 23: 4097-4100.
6. Cameron C, Pebody R (2006) Introduction of pneumococcal conjugate vaccine to the UK childhood immunisation programme, and changes to the meningitis C and Hib schedules. Euro.Surveill 11: E060302.
7. Richmond P, Borrow R, Goldblatt D, Findlow J, Martin S, et al. (2001) Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect. Dis 183: 160-163.
8. Snape MD, Kelly DF, Green B, Moxon ER, Borrow R, et al. (2005) Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr.Infect.Dis J 24: 128-131.
9. Snape MD, Kelly DF, Lewis S, Banner C, Kibwana L, et al. (2008) Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 7659: 1487-1491.
10. Trotter CL, Borrow R, Findlow J, Holland A, Frankland S (2008) Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin Vaccine Immunol 15: 1694-1698.
11. Borrow R, Andrews N, Goldblatt D, Miller E (2001) Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 69: 1568-1573.
12. Borrow R, Balmer P, Miller E (2005) Meningococcal surrogates of protection--serum bactericidal antibody activity. Vaccine 23: 2222-2227.
13. Backhouse JL, Gidding HF, MacIntyre CR, McIntyre PB, Gilbert GL (2007) Population-based seroprevalence of Neisseria meningitidis serogroup C capsular antibody before the introduction of conjugate vaccine, in Australia. Vaccine 25: 1310-1315.
14. Ceyhan M, Yildirim I, Balmer P, Riley C, Laher G, et al. (2007) Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005. Vaccine 25: 7233-7237.
15. de Melker HE, Conyn-van Spaendonck MA (1998) Immunosurveillance and the evaluation of national immunization programmes: a population-based approach. Epidemiol.Infect 121: 637-643.
16. van der Klis FR, Mollema L, Berbers GA, de Melker HE, Coutinho RA (2009) Second national serum bank for population-based seroprevalence studies in the Netherlands. Neth J Med 67: 301-308.
17. de Voer RM, Schepp RM, Versteegh FG, van der Klis FR, Berbers GA (2009) Simultaneous detection of Haemophilus influenzae type b polysaccharidespecific antibodies and Neisseria meningitidis serogroup A, C, Y, and W-135 polysaccharide-specific antibodies in a fluorescent-bead-based multiplex immunoassay. Clin.Vaccine Immunol 16: 433-436.
18. van Gageldonk PG, van Schaijk FG, van der Klis FR, Berbers GA (2008) Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol Methods 335: 79-89.
19. Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, et al. (1997) Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 4: 156-167.
20. Goldblatt D, Vaz AR, Miller E (1998) Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 177: 1112-1115.
21. Bredius RG, Driedijk PC, Schouten MF, Weening RS, Out TA (1992) Complement activation by polyclonal immunoglobulin G1 and G2 antibodies against Staphylococcus aureus, Haemophilus influenzae type b, and tetanus toxoid. Infect Immun 60: 4838-4847.
22. Sakou II, Tzanakaki G, Tsolia MN, Sioumala M, Barbouni A, et al. (2009) Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine. Vaccine 33: 4408-4411.
23. Southern J, Borrow R, Andrews N, Morris R, Waight P, et al. (2009) Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin Vaccine Immunol 16: 194-199.
24. Díez-Domingo J, Planelles Cantarino MV, Baldó Torrentí JM, Sansano MI, Rosich AJ, et al. (2010) A Randomized, Multicenter, Open-Label Clinical Trial to Assess the Immunogenicity of a Meningococcal C Vaccine Booster Dose Administered to Children Aged 14 to 18 Months. Pediatr Infect Dis J 29: 148-152.
25. Borrow R, Andrews N, Findlow H, Waight P, Southern J, et al. (2010) Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 17: 154-159.
26. Goldschneider I, Gotschlich EC, Artenstein MS (1969) Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp.Med 129: 1307-1326.
27. Weill JC, Weller S, Reynaud CA (2009) Human marginal zone B cells. Annu Rev Immunol 27: 267-285.
28. Upham JW, Lee PT, Holt BJ, Heaton T, Prescott SL, et al. (2002) Development of interleukin-12-producing capacity throughout childhood. Infect Immun 70: 6583-6588.
29. Pihlgren M, Friedli M, Tougne C, Rochat AF, Lambert PH, et al. (2006) Reduced ability of neonatal and early-life bone marrow stromal cells to support plasmablast survival. J Immunol 176: 165-172.
30. Feiring B, Fuglesang J, Oster P, Naess LM, Helland OS, et al. (2006) Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine. Clin Vaccine Immunol 13: 790-796.
31. Campbell H, Andrews N, Borrow R, Trotter C, Miller E (2010) Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 17: 840-847.
32. Blanchard RG, Snape MD, Kelly DF, John T, Morant A (2008) The magnitude of the antibody and memory B cell responses during priming with a protein polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. J Immunol 180: 2165-2173.
33. de Voer RM, van der Klis FR, Nooitgedagt JE, Versteegh FG, van Huisseling JC, et al. (2009) Seroprevalence and placental transportation of maternal antibodies specific for Neisseria meningitidis serogroup C, Haemophilus influenzae type B, diphtheria, tetanus, and pertussis. Clin Infect Dis 49: 58-64.
34. O'Dempsey TJ, McArdle T, Ceesay SJ, Secka O, Demba E, et al. (1996) Meningococcal antibody titres in infants of women immunised with meningococcal polysaccharide vaccine during pregnancy. Arch Dis Child Fetal Neonatal Ed 74: F43-F46.
35. Goldschneider I, Gotschlich EC, Artenstein MS (1969) Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 129: 1327-1348.
36. Maiden MC, Stuart JM (2002) Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359: 1829-1831.
37. Robbins JB, Myerowitz L, Whisnant JK, Argaman M, Schneerson R, et al. (1972) Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3. Infect Immun 6: 651-656.
38. Myerowitz RL, Gordon RE, Robbins JB (1973) Polysaccharides of the genus Bacillus cross-reactive with the capsular polysaccharides of Diplococcus pneumoniae type 3, Haemophilus influenzae type b, and Neisseria meningitidis group A. Infect Immun 8: 896-900.
39. Vann WF, Liu TY, Robbins JB (1976) Bacillus pumilus polysaccharide crossreactive with meningococcal group A polysaccharide. Infect Immun 13: 1654-1662.
40. Snape MD, Kelly DF, Salt P, Green S, Snowden C, et al. (2006) Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis 43: 1387-1394.
41. de Voer RM, van der Klis FR, Engels CW, Schepp RM, van de Kassteele J, et al. (2009) Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults. Vaccine 27: 6974-6982.
42. Richmond P, Borrow R, Miller E, Clark S, Sadler F, et al. (1999) Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 179: 1569-1572.